Elekta
66,3 SEK -1,56%11 investorer følger denne virksomhed
Elekta provides medical technology. The company specializes in the development of clinical solutions for the treatment of cancer and brain diseases. Elekta's treatment system and planning software for radiation therapy and radiation surgery as well as other software systems are used in the healthcare industry to identify and analyze various health conditions. Operations are conducted on a global level, with headquarters in Stockholm.
Omsætning
18,12 mia.
EBIT %
11,25 %
P/E
19,44
Udbytteafkast, %
3,62 %
Kursmål
-
Anbefaling
-
Opdateret
-
NASDAQ Stockholm
EKTA B
Daglig lav / høj pris
66,25 / 67,7
SEK
Markedsværdi
25,43 mia. SEK
Aktieomsætning
30,23 mio. SEK
Volumen
450 t
Finanskalender
Delårsrapport
27.11.2024
Delårsrapport
21.02.2025
Årsrapport
28.05.2025
Større aktionærerKilde: Millistream Market Data AB
Ejer | Kapital | Stemmer |
---|---|---|
Fjärde AP-fonden | 9,1 % | 6,7 % |
Laurent Leksell fam och bolag | 5,7 % | 30,2 % |
T. Rowe Price | 4,5 % | 3,3 % |
Nordea funds | 3,8 % | 2,8 % |
SEB Funds | 3,6 % | 2,7 % |
Vanguard | 3,4 % | 2,5 % |
AMF Pension & Fonder | 3,2 % | 2,4 % |
Handelsbanken Fonder | 3,0 % | 2,2 % |
Lannebo Kapitalförvaltning AB | 3,0 % | 2,3 % |
Swedbank Robur Fonder | 2,6 % | 1,9 % |
ViserAlle indholdstyper
Elekta issues a SEK 1.5 billion bond and signs a revolving credit facility of SEK 1 billion
Elekta Evo submitted to U.S. FDA for premarket approval – to be featured at ASTRO
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools